Stockscreener 앱 받기
20.68
5.35%
1.05
시간 외 거래:
20.58
-0.10
-0.48%
전일 마감가:
$19.63
열려 있는:
$19.82
하루 거래량:
513.48K
Relative Volume:
0.69
시가총액:
$1.13B
수익:
$199.89M
순이익/손실:
$52.48M
주가수익비율:
24.33
EPS:
0.85
순현금흐름:
$61.15M
1주 성능:
+4.66%
1개월 성능:
+59.57%
6개월 성능:
+153.43%
1년 성능:
+36.50%
1일 변동 폭
$19.55
$20.90
1주일 범위
$18.80
$20.90
52주 변동 폭
$5.35
$20.90
Stoke Therapeutics Inc Stock (STOK) Company Profile
명칭
Stoke Therapeutics Inc
전화
781-430-8200
주소
45 WIGGINS AVENUE, BEDFORD, MA
STOK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
20.68 | 1.08B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-18 | 개시 | Jefferies | Buy |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-03-26 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-07-25 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 재개 | Canaccord Genuity | Buy |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-10-24 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 개시 | Jefferies | Buy |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-11-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 개시 | UBS | Neutral |
| 2021-05-10 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-12-11 | 재확인 | Needham | Buy |
| 2020-10-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-09-29 | 개시 | Needham | Buy |
| 2019-12-18 | 개시 | Wedbush | Outperform |
| 2019-11-12 | 개시 | BTIG Research | Buy |
| 2019-10-25 | 개시 | H.C. Wainwright | Buy |
| 2019-07-15 | 개시 | Canaccord Genuity | Buy |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Credit Suisse | Outperform |
| 2019-07-15 | 개시 | JP Morgan | Overweight |
모두보기
Stoke Therapeutics Inc 주식(STOK)의 최신 뉴스
Will Stoke Therapeutics Inc. outperform its industry peersJuly 2025 Summary & Stepwise Trade Signal Guides - خودرو بانک
Stoke Therapeutics stock reaches 52-week high at 20.5 USD By Investing.com - Investing.com Canada
Is Stoke Therapeutics Inc. part of any major indexQuarterly Market Review & Fast Moving Stock Trade Plans - خودرو بانک
Why is Stoke Therapeutics Inc. stock going upMarket Growth Review & Technical Entry and Exit Tips - خودرو بانک
Will breakout in Stoke Therapeutics Inc. lead to full recoveryJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
Is Stoke Therapeutics Inc. still worth holding after the dipRisk Management & Technical Pattern Based Buy Signals - Newser
Volume spikes in Stoke Therapeutics Inc. stock – what they mean2025 Trading Volume Trends & AI Driven Stock Price Forecasts - Newser
Analyzing drawdowns of Stoke Therapeutics Inc. with statistical tools2025 Geopolitical Influence & Low Risk Entry Point Tips - Newser
Published on: 2025-09-05 21:40:33 - خودرو بانک
Stoke Therapeutics stock reaches 52-week high at 20.5 USD - Investing.com
Price action breakdown for Stoke Therapeutics Inc.July 2025 Institutional & High Win Rate Trade Tips - Newser
Key metrics from Stoke Therapeutics Inc.’s quarterly data2025 Momentum Check & Expert Verified Movement Alerts - Newser
Applying Wyckoff theory to Stoke Therapeutics Inc. stock2025 Market Overview & Fast Moving Trade Plans - Newser
Relative strength of Stoke Therapeutics Inc. in sector analysisTrade Entry Summary & Entry Point Strategy Guides - Newser
Sector ETF performance correlation with Stoke Therapeutics Inc.Market Rally & Low Drawdown Investment Ideas - Newser
Market reaction to Stoke Therapeutics Inc.’s recent newsWeekly Gains Report & Entry Point Strategy Guides - Newser
How to use Fibonacci retracement on Stoke Therapeutics Inc.Bull Run & Free Safe Entry Trade Signal Reports - Newser
A | Is Stoke Therapeutics, Inc. a turnaround storyQuarterly Growth Report & Daily Risk Controlled Trade Plans - خودرو بانک
Can volume confirm reversal in Stoke Therapeutics Inc.Weekly Market Outlook & Precise Buy Zone Tips - Newser
What does recent volatility data suggest for Stoke Therapeutics Inc.Portfolio Update Report & Low Risk Investment Opportunities - Newser
Stoke Therapeutics Inc. recovery potential after sell off2025 Market Overview & Risk Managed Investment Entry Signals - Newser
Will Stoke Therapeutics Inc. bounce back from current supportQuarterly Profit Review & Short-Term High Return Ideas - Newser
Insider Sell: Kaye Edward M. MD Sells 61,885 Shares of Stoke The - GuruFocus
Will Stoke Therapeutics Inc. stock go up in YEARJuly 2025 Drop Watch & Consistent Profit Trading Strategies - خودرو بانک
Institutional scanner results for Stoke Therapeutics Inc.2025 Breakouts & Breakdowns & Verified Momentum Stock Alerts - Newser
Building trade automation scripts for Stoke Therapeutics Inc.Bull Run & Technical Confirmation Trade Alerts - Newser
Stoke Therapeutics' Insider Sales: A Cautionary Tale or a Sign of Strength? - AInvest
Assessing Insider Selling Trends at Stoke Therapeutics (STOK): Liquidity Moves or Loss of Confidence? - AInvest
Stoke Therapeutics Executives Buy and Sell Shares in August and September 2025. - AInvest
Will Stoke Therapeutics Inc. benefit from rate cutsQuarterly Profit Summary & Free Technical Confirmation Trade Alerts - خودرو بانک
What analysts say about Stoke Therapeutics Inc. stockJuly 2025 Sentiment & Precise Swing Trade Entry Alerts - خودرو بانک
Stoke Therapeutics shares fall 2.40% premarket after presenting data from Phase 1/2a and open-label extension studies of zorevunersen. - AInvest
Can a trend reversal in Stoke Therapeutics Inc. lead to recoveryIndex Update & Risk Controlled Swing Trade Alerts - Newser
What’s next for Stoke Therapeutics Inc. stock pricePortfolio Risk Summary & Stock Portfolio Risk Management - Newser
What are the risks of holding Stoke Therapeutics Inc.Quarterly Profit Summary & Long-Term Growth Portfolio Plans - خودرو بانک
Is Stoke Therapeutics Inc. stock ready for a breakoutJuly 2025 Update & Community Supported Trade Ideas - Newser
All presentations are available for download on the Stoke Therapeutics website under the Investors & News tab. - Placera.se
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome | BIIB - GuruFocus
Biogen and Stoke Therapeutics Announce Three-Year Results Supporting Zorevunersen's Promise for Dravet Syndrome Treatment - Quiver Quantitative
Biogen and Stoke Therapeutics Present Data at the 36th - GlobeNewswire
Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome - Biogen
Biogen Inc. - Via Ritzau
Stoke Therapeutics Inc (STOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Stoke Therapeutics Inc 주식 (STOK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kaye Edward M. MD | Director |
Sep 03 '25 |
Sale |
20.13 |
45,996 |
925,858 |
91,585 |
| Kaye Edward M. MD | Director |
Sep 02 '25 |
Sale |
20.14 |
14,860 |
299,260 |
137,581 |
| Kaye Edward M. MD | Director |
Aug 29 '25 |
Sale |
20.00 |
1,029 |
20,580 |
152,441 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Sep 02 '25 |
Option Exercise |
7.07 |
9,150 |
64,690 |
33,098 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 29 '25 |
Option Exercise |
7.07 |
850 |
6,010 |
24,798 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Sep 02 '25 |
Sale |
20.14 |
14,922 |
300,492 |
18,176 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Sep 03 '25 |
Sale |
20.07 |
6,345 |
127,317 |
11,831 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 29 '25 |
Sale |
20.00 |
850 |
17,000 |
23,948 |
1.40%
자본화:
|
볼륨(24시간):